Malignant Pleural Effusion
IPC vs talc pleurodesis, trapped lung, and thoracoscopic management of MPE.
Overview
Malignant pleural effusion (MPE) occurs when tumour cells involve the pleural space — either by direct invasion, haematogenous seeding, or lymphatic obstruction. It is the second most common cause of exudative pleural effusion after parapneumonic effusion. MPE indicates advanced disease and significantly impacts quality of life through progressive dyspnoea.
Aetiology
Lung cancer and breast cancer together account for approximately 50–60% of all MPEs. Other common primary sites include ovary, stomach, and lymphoma.
Diagnosis
MPE is an exudate by Light's criteria. The effusion is typically haemorrhagic or serosanguinous. Positive cytology on pleural fluid confirms the diagnosis in 60–70% — sensitivity increases with second sample. If cytology is negative and malignancy is strongly suspected, thoracoscopy-guided pleural biopsy provides near-100% diagnostic yield and simultaneous assessment for pleurodesis.
- CT thorax: identifies pleural thickening, nodularity, loculations, and primary tumour if not yet diagnosed
- PET-CT: useful for identifying the primary and assessing extent of systemic disease
- Thoracoscopy: gold standard for diagnosis when fluid cytology is negative — visual inspection of pleura, targeted biopsy, and talc poudrage pleurodesis at same sitting
Before committing to pleurodesis, confirm the lung re-expands fully after drainage. If the lung is trapped by tumour encasement (visceral pleural coating), the pleural space cannot be obliterated and pleurodesis will fail. In trapped lung, an indwelling pleural catheter (IPC) is the preferred long-term drainage strategy.
Management
| Option | Indication | Notes |
|---|---|---|
| Observation | Small, asymptomatic effusion | Monitor; treat underlying malignancy |
| Therapeutic thoracentesis | Symptomatic; assessment of lung re-expansion | Temporary relief; high recurrence rate; repeated procedures increase risk |
| Indwelling pleural catheter (IPC) | Symptomatic effusion; trapped lung; patient preference for outpatient management | Patient-controlled drainage; spontaneous pleurodesis in ~50% after 6–8 weeks; preferred in short prognosis |
| Talc pleurodesis (via drain or thoracoscopy) | Expandable lung; reasonable performance status; prognosis >3 months | Talc poudrage via thoracoscope has highest success rate (~80%); slurry via chest tube ~60–70% |
| Thoracoscopic pleurectomy / abrasion | Failed chemical pleurodesis | Reserved for good PS patients; mechanical pleurodesis |
| Pleuroperitoneal shunt | Trapped lung; failed pleurodesis; poor surgical risk | Patient-pumped valve; useful in selected cases |
The TIME2 trial and subsequent studies show IPC and talc pleurodesis are equivalent in symptom control. IPC requires fewer hospitalisations and is preferred for patients with trapped lung or short prognosis. Spontaneous pleurodesis occurs in ~50% of IPC patients, potentially avoiding further procedures. The choice should be individualised based on lung expandability, prognosis, patient preference, and local expertise.
All clinical content should be verified against current guidelines before clinical application. This resource is intended for revision and educational purposes only.
Standard textbooks
- Shields TW, LoCicero J, Reed CE, Feins RH. General Thoracic Surgery. 7th ed. Lippincott Williams & Wilkins.
- Sellke FW, del Nido PJ, Swanson SJ. Sabiston & Spencer Surgery of the Chest. 9th ed. Elsevier.
- Pearson FG, et al. Thoracic Surgery. 3rd ed. Churchill Livingstone.